Bereich
Brustzentrum St.Gallen
BZ · Dept. IV
Treatment concepts of oral cancer.
Bredell M, Rordorf T, Studer G. Treatment concepts of oral cancer. SADJ 2012; 67:574-6.
01.11.2012Treatment concepts of oral cancer.
01.11.2012SADJ 2012; 67:574-6
Bredell M G, Rordorf Tamara, Studer G
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
Ewertz M, Goldhirsch A, Coates A, Smith I, Láng I, Colleoni M, Gelber R, Rabaglio M, Paridaens R, Forbes J, Bonnefoi H, Thürlimann B, Price K, Ejlertsen B, Regan M, Gray K, Mouridsen H. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 2012; 30:3967-75.
08.10.2012Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
08.10.2012J Clin Oncol 2012; 30:3967-75
Ewertz Marianne, Goldhirsch Aron, Coates Alan S, Smith Ian E, Láng István, Colleoni Marco, Gelber Richard D, Rabaglio Manuela, Paridaens Robert J, Forbes John F, Bonnefoi Hervé, Thürlimann Beat, Price Karen N, Ejlertsen Bent, Regan Meredith M, Gray Kathryn P, Mouridsen Henning T
Imaging of bone metastases in prostate cancer: an update
Langsteger W, Haim S, Knauer M, Waldenberger P, Emmanuel K, Loidl W, Wolf I, Beheshti M. Imaging of bone metastases in prostate cancer: an update. Q J Nucl Med Mol Imaging 2012; 56:447-58.
01.10.2012Imaging of bone metastases in prostate cancer: an update
01.10.2012Q J Nucl Med Mol Imaging 2012; 56:447-58
Langsteger W, Haim S, Knauer Michael, Waldenberger P, Emmanuel K, Loidl W, Wolf I, Beheshti M
Treatment of breast cancer in the elderly: a prospective, population-based Swiss study
Jörger M, Jundt G, Probst-Hensch N, Bordoni A, Konzelmann I, Bouchardy C, Vlastos G, Lütolf U, Rageth C, Frick H, Savidan A, Thürlimann B, Ess S. Treatment of breast cancer in the elderly: a prospective, population-based Swiss study. J Geriatr Oncol 2012; 4:39-47.
24.08.2012Treatment of breast cancer in the elderly: a prospective, population-based Swiss study
24.08.2012J Geriatr Oncol 2012; 4:39-47
Jörger Markus, Jundt G, Probst-Hensch N, Bordoni A, Konzelmann I, Bouchardy C, Vlastos G, Lütolf U, Rageth C, Frick H, Savidan A, Thürlimann Beat, Ess S
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer
Lutz M, Oyama T, Roth A, Rueschoff J, Ruhstaller T, Seruca R, Stahl M, Sterzing F, van Cutsem E, van der Gaast A, van Lanschot J, Ychou M, Moehler M, Mariette C, Lordick F, Zalcberg J, Ducreux M, Ajani J, Allum W, Aust D, Bang Y, Cascinu S, Hölscher A, Jankowski J, Jansen E, Kisslich R, Otto F. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer 2012; 48:2941-53.
23.08.2012Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer
23.08.2012Eur J Cancer 2012; 48:2941-53
Lutz Manfred P, Oyama Tsuneo, Roth Arnaud, Rueschoff Josef, Ruhstaller Thomas, Seruca Raquel, Stahl Michael, Sterzing Florian, van Cutsem Eric, van der Gaast Ate, van Lanschot Jan, Ychou Marc, Moehler Markus, Mariette Christophe, Lordick Florian, Zalcberg John R, Ducreux Michel, Ajani Jaffer A, Allum William, Aust Daniela, Bang Yung-Jue, Cascinu Stefano, Hölscher Arnulf, Jankowski Janusz, Jansen Edwin P M, Kisslich Ralf, Otto Florian
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial
Witzel I, Rack B, Meinhold-Heerlein I, Liedtke C, Karn T, Huober J, Zu Eulenburg C, Issa-Nummer Y, Untch M, Schem C, Mau C, Fasching P, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F, Schmatloch S, Hauschild M, Bischoff J, Müller V. Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial. Br J Cancer 2012; 107:956-60.
14.08.2012Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial
14.08.2012Br J Cancer 2012; 107:956-60
Witzel I, Rack B, Meinhold-Heerlein I, Liedtke C, Karn T, Huober Jens, Zu Eulenburg C, Issa-Nummer Y, Untch M, Schem C, Mau C, Fasching P A, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F, Schmatloch S, Hauschild M, Bischoff J, Müller V
Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report
Karlsson P, Gruber G, Goldhirsch A, Gelber R, Forbes J, Castiglione-Gertsch M, Crivellari D, Thürlimann B, Kovács A, Collins J, Lindtner J, Price K, Chua B, Cole B, International Breast Cancer Study Group. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. Ann Oncol 2012; 23:2852-8.
09.07.2012Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report
09.07.2012Ann Oncol 2012; 23:2852-8
Karlsson P, Gruber G, Goldhirsch A, Gelber R D, Forbes J F, Castiglione-Gertsch M, Crivellari D, Thürlimann Beat, Kovács A, Collins J P, Lindtner J, Price K N, Chua B H, Cole B F, International Breast Cancer Study Group
Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials
Huober J, Regan M, Gelber R, Price K, Öhlschlegel C, Viale G, Coates A, Goldhirsch A, Gelber S, Thürlimann B. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol 2012; 23:2843-51.
14.06.2012Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials
14.06.2012Ann Oncol 2012; 23:2843-51
Huober Jens, Regan M M, Gelber R D, Price K N, Öhlschlegel Christian, Viale G, Coates A S, Goldhirsch A, Gelber S, Thürlimann Beat
Follow up after IMRT in oral cavity cancer: update.
Studer G, Brown M, Bredell M, Graetz K, Huber G, Linsenmeier C, Najafi Y, Riesterer O, Rordorf T, Schmid S, Glanzmann C. Follow up after IMRT in oral cavity cancer: update. Radiat Oncol 2012; 7:84.
11.06.2012Follow up after IMRT in oral cavity cancer: update.
11.06.2012Radiat Oncol 2012; 7:84
Studer Gabriela, Brown Michelle L, Bredell Marius, Graetz Klaus W, Huber Gerhard, Linsenmeier Claudia, Najafi Yousef, Riesterer Oliver, Rordorf Tamara, Schmid Stephan, Glanzmann Christoph
VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5
Herr D, Sallmann A, Bekes I, Konrad R, Holzheu I, Kreienberg R, Wulff C. VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5. Gynecol Oncol 2012; 127:210-6.
08.05.2012VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5
08.05.2012Gynecol Oncol 2012; 127:210-6
Herr Daniel, Sallmann Alexandra, Bekes Inga, Konrad Regina, Holzheu Iris, Kreienberg Rolf, Wulff Christine
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV
Meier W, Burges A, Stähle A, Belau A, Schröder W, Richter B, Wimberger P, Schmalfeldt B, Canzler U, Kreienberg R, Wollschlaeger K, Huober J, Baumann K, Gropp-Meier M, Rau J, du Bois A, Sehouli J. Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV. Gynecol Oncol 2012; 126:236-40.
04.05.2012Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV
04.05.2012Gynecol Oncol 2012; 126:236-40
Meier Werner, Burges Alexander, Stähle Anne, Belau Antje, Schröder Willibald, Richter Barbara, Wimberger Pauline, Schmalfeldt Barbara, Canzler Ulrich, Kreienberg Rolf, Wollschlaeger Kerstin, Huober Jens, Baumann Klaus, Gropp-Meier Martina, Rau Jörn, du Bois Andreas, Sehouli Jalid
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
Ribi K, BIG 1-98 Collaborative Group, Bernhard J, Gelber R, Price K, Goldhirsch A, Coates A, Pagani O, Cardoso F, Thürlimann B, Harvey V, Thompson A, Phillips K, Aldridge J, International Breast Cancer Study Group. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer 2012; 106:1618-25.
24.04.2012Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
24.04.2012Br J Cancer 2012; 106:1618-25
Ribi K, BIG 1-98 Collaborative Group, Bernhard J, Gelber R D, Price K N, Goldhirsch A, Coates A S, Pagani O, Cardoso F, Thürlimann Beat, Harvey V, Thompson A, Phillips K-A, Aldridge J, International Breast Cancer Study Group
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
von Minckwitz G, Mehta K, Nekljudova V, Denkert C, Konecny G, Kaufmann M, Jackisch C, Huober J, Hilfrich J, Eiermann W, Gerber B, Fasching P, Eidtmann H, Costa S, Blohmer J, Untch M, Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30:1796-804.
16.04.2012Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
16.04.2012J Clin Oncol 2012; 30:1796-804
von Minckwitz Gunter, Mehta Keyur, Nekljudova Valentina, Denkert Carsten, Konecny Gottfried E, Kaufmann Manfred, Jackisch Christian, Huober Jens, Hilfrich Jörn, Eiermann Wolfgang, Gerber Bernd, Fasching Peter A, Eidtmann Holger, Costa Serban D, Blohmer Jens-Uwe, Untch Michael, Loibl Sibylle
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer
Jörger M, ess s, Dehler S, Savidan A, Bouchardy C, Frick H, Konzelmann I, Thürlimann B. A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer. Swiss Med Wkly 2012; 142:w13571.
11.04.2012A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer
11.04.2012Swiss Med Wkly 2012; 142:w13571
Jörger Markus, ess silvia, Dehler Silvia, Savidan Anita, Bouchardy Christine, Frick Harald, Konzelmann Isabelle, Thürlimann Beat
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
Regan M, Debled M, Maibach R, Price K, Gelber R, Coates A, Goldhirsch A, Rae J, Viale G, Neven P, Ditzel H, Lyng M, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012; 104:441-51.
06.03.2012CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
06.03.2012J Natl Cancer Inst 2012; 104:441-51
Regan Meredith M, Debled Marc, Maibach Rudolf, Price Karen N, Gelber Richard D, Coates Alan S, Goldhirsch Aron, Rae James M, Viale Giuseppe, Neven Patrick, Ditzel Henrik J, Lyng Maria B, Leyland-Jones Brian, Bouzyk Mark, Pagani Olivia, Tang Weining, Kammler Roswitha, Dell'Orto Patrizia, Biasi Maria Olivia, Thürlimann Beat, Breast International Group (BIG) 1-98 Collaborative Group
Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients
Solomayer E, Wallwiener D, Wackwitz B, Krämer B, Huober J, Becker S, Lück H, Janni W, Hirnle P, Gebauer G, Fehm T. Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol 2012; 23:2271-2277.
01.03.2012Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients
01.03.2012Ann Oncol 2012; 23:2271-2277
Solomayer E-F, Wallwiener D, Wackwitz B, Krämer B, Huober Jens, Becker S, Lück H-J, Janni W, Hirnle P, Gebauer G, Fehm T
Results of the First Austrian Multidisciplinary Expert Panel on Controversies in Local Treatment of Breast Cancer
Knauer M, Gnant M, Fitzal F. Results of the First Austrian Multidisciplinary Expert Panel on Controversies in Local Treatment of Breast Cancer. Breast Care (Basel) 2012; 7:61-66.
20.02.2012Results of the First Austrian Multidisciplinary Expert Panel on Controversies in Local Treatment of Breast Cancer
20.02.2012Breast Care (Basel) 2012; 7:61-66
Knauer Michael, Gnant Michael, Fitzal Florian
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
von Minckwitz G, Blohmer J, Huober J, Hauschild M, Fehm T, Müller B, Denkert C, Loibl S, Nekljudova V, Untch M, German Breast Group, Kunz G, Jackisch C, Gerber B, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366:299-309.
26.01.2012Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
26.01.2012N Engl J Med 2012; 366:299-309
von Minckwitz Gunter, Blohmer Jens-Uwe, Huober Jens, Hauschild Maik, Fehm Tanja, Müller Berit Maria, Denkert Carsten, Loibl Sibylle, Nekljudova Valentina, Untch Michael, German Breast Group, Kunz Georg, Jackisch Christian, Gerber Bernd, Eidtmann Holger, Rezai Mahdi, Fasching Peter A, Tesch Hans, Eggemann Holm, Schrader Iris, Kittel Kornelia, Hanusch Claus, Kreienberg Rolf, Solbach Christine, Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Untch M, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G, German Breast Group (GBG), Hanusch C, Tesch H, Kreienberg R, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J, Hilfrich J, Strumberg D, Fasching P, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012; 13:135-44.
17.01.2012Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
17.01.2012Lancet Oncol 2012; 13:135-44
Untch Michael, Gerber Bernd, Rezai Mahdi, Jackisch Christian, Huober Jens, Kühn Thorsten, Nekljudova Valentina, von Minckwitz Gunter, German Breast Group (GBG), Hanusch Claus, Tesch Hans, Kreienberg Rolf, Loibl Sibylle, Bischoff Joachim, Eidtmann Holger, Kaufmann Manfred, Blohmer Jens-Uwe, Hilfrich Jörn, Strumberg Dirk, Fasching Peter A, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group
Brain metastases free survival differs between breast cancer subtypes
Berghoff A, Preusser M, Steger G, Zielinski C, Gnant M, Mader R, Dieckmann K, Fitzal F, Eiter H, Knauer M, Rottenfusser A, Rudas M, Pluschnig U, Dubsky P, De Vries C, Bago-Horvath Z, Bartsch R. Brain metastases free survival differs between breast cancer subtypes. Br J Cancer 2012; 106:440-6.
10.01.2012Brain metastases free survival differs between breast cancer subtypes
10.01.2012Br J Cancer 2012; 106:440-6
Berghoff A, Preusser M, Steger G G, Zielinski C C, Gnant M, Mader R M, Dieckmann K, Fitzal F, Eiter H, Knauer Michael, Rottenfusser A, Rudas M, Pluschnig U, Dubsky P, De Vries C, Bago-Horvath Z, Bartsch R